EMA Authorised: Vargatef (nintedanib) — Boehringer Ingelheim International GmbH

View source ↗

Summary

Approval of Vargatef (nintedanib) by EMA for non-small cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Vargatef

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Boehringer Ingelheim International GmbH. Decision date: 10/06/2026